We are aware of a number of guidelines on hypertension published by different bodies. British Heart Society (BHS) and National Health Institute for Clinical Excellence (NICE) published their guideline in 2011 which has been updated in 2013.
European Society of Hypertension and European Society of Cardiology have the " Guideline for the management of arterial hypertension" in 2013. American College of Cardiology (ACC) and American Heart Association (AHA) jointly issued a guideline in 2013. Much awaited Joint National Committee (JNC) VIII report has been published in 2014 -" Evidence -based guideline for the management of high blood pressure in adults" All these guidelines have some points to differ. BHS/NICE guideline classify hypertension as Stage I hypertension (>140/90mmHg) ; Stage II hypertension (>160/100mmHg) and severe hypertension (>180/110mmHg). ESH/ESC guideline make an elaborate classification of blood pressure (instead of simply hypertension): Optimal (<120/80mmHg); Normal (120-129/80-84 mmHg); High normal ( 130-139/85-89mmHg);Grade 1 hypertension (140-159 &/or 90-99mmHg); Grade 2 (160-179 &/or 100-109mmHg); Grade 3 ( >180&/or >110mmHg) and Isolated systolic hypertension (SBP >140 and DBP<90).ACC/AHA simply categorize hypertension as Stage 1 hypertension ( 140-159 &/or 90-99mmHg) and Stage 2 hypertension (>160 &/or >100 mmHg). JNC VIII report does not classify the stages/grades of blood pressure. Rather it sets threshold for initiating antihypertensive treatment.
The guidelines mention the preferred initiating drugs in their recommendation. ACC/AHA and ESH/ESC guidelines recommend 5 class of drugs -ACEIs, ARBs, CCBs, BBs and diuretics as the pharmacotherapy. But BHS/NICE and JNC VIII reserved the beta-blockers in selected patients (e.g. in resistant hypertension).
All the mentioned guidelines are based on the data that donot include our population or the population ). Experts of the guideline suggest 4 class of drugs ( diuretics; ACEI;ARB and CCB ) as the preferred drugs. They put a comment " given the low cost and availability of beta-blockers, it may be considered in certain settings".
In different aspects ,Indian and Bangladesh guidelines have many points in common ( though Bangladesh guidelines suggest mercury sphygmomanometer and Indian guidelines oppose the use of mercury and suggest aneroid machine.
What we need in the future is evidence based guideline rather than the guideline based mainly on expert opinion. We have to have broader population-based epidemiological studies to get data of prevalence of hypertension in different regions of the country with different food, particularly salt intake, habit as well as in different sub-sets of people of varied socio-economic condition and occupation. Effective doses of different antihypertensive drugs with possible variation of metabolism of drugs need to be explored more.
We may hope that in the next few years we may develop guidelines for our own population and physicians that will be based more on the evidence based data.
